Literature DB >> 29113452

Raised Fibrinogen Levels and Outcome in Outpatients With Peripheral Artery Disease.

Pere Altes1, Paulina Perez1, Carlos Esteban1, Juan Francisco Sánchez Muñoz-Torrero2, Eduardo Aguilar3, Ana María García-Díaz4, Lorenzo Ramón Álvarez5, Pedro Enrique Jiménez6, Joan Carles Sahuquillo7, Manuel Monreal8.   

Abstract

The influence of raised fibrinogen levels on outcome in stable outpatients with peripheral arterial disease (PAD) has not been consistently investigated. We used data from the Factores de Riesgo y ENfermedad Arterial (FRENA) registry to compare ischemic events, major bleeding, and mortality in stable outpatients with PAD, according to their baseline plasma fibrinogen levels. Of 1363 outpatients with PAD recruited in FRENA, 558 (41%) had fibrinogen levels >450 mg/100 mL. Over 18 months, 43 patients presented with acute myocardial infarction, 37 had an ischemic stroke, 51 underwent limb amputation, 19 had major bleeding, and 90 died. Compared to patients with normal levels, those with raised fibrinogen levels had an over 2-fold higher rate of ischemic stroke (rate ratio [RR]: 2.30; 95% confidence interval [CI]: 1.19-4.59), limb amputation (RR: 2.58; 95% CI: 1.46-4.67), or death (RR: 2.27; 95% CI: 1.49-3.51) and an over 3-fold higher rate of major bleeding (RR: 3.90; 95% CI: 1.45-12.1). On multivariate analysis, patients with raised fibrinogen levels had an increased risk of developing subsequent ischemic events (hazard ratio [HR]: 1.61; 95% CI: 1.11-2.32) and major bleeding (HR: 3.42; 95% CI: 1.22-9.61). Stable outpatients with PAD and raised plasma fibrinogen levels had increased rates of subsequent ischemic events and major bleeding.

Entities:  

Keywords:  cardiovascular diseases; fibrinogen; intermittent claudication; outcome; peripheral artery disease

Mesh:

Substances:

Year:  2017        PMID: 29113452     DOI: 10.1177/0003319717739720

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  5 in total

1.  Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option critical limb ischemia.

Authors:  Tianyue Pan; Hao Liu; Yuan Fang; Zheng Wei; Shiyang Gu; Gang Fang; Yifan Liu; Yang Luo; Daqiao Guo; Xin Xu; Bin Chen; Junhao Jiang; Jue Yang; Zhenyu Shi; Ting Zhu; Yun Shi; Peng Liu; Zhihui Dong; Weiguo Fu
Journal:  Stem Cell Res Ther       Date:  2019-01-11       Impact factor: 6.832

2.  Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans.

Authors:  Ji Sun; Qiang Deng; Jun Wang; Shoupeng Duan; Huaqiang Chen; Huixin Zhou; Zhen Zhou; Fu Yu; Fuding Guo; Chengzhe Liu; Saiting Xu; Lingpeng Song; Yijun Wang; Hui Feng; Lilei Yu
Journal:  Front Cardiovasc Med       Date:  2022-04-04

Review 3.  Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy.

Authors:  Farwa Altaf; Shourong Wu; Vivi Kasim
Journal:  Front Mol Biosci       Date:  2021-05-28

Review 4.  Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.

Authors:  José Miguel Rivera-Caravaca; Anny Camelo-Castillo; Inmaculada Ramírez-Macías; Pablo Gil-Pérez; Cecilia López-García; María Asunción Esteve-Pastor; Esteban Orenes-Piñero; Antonio Tello-Montoliu; Francisco Marín
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 5.  The Role of Circulating Biomarkers in Peripheral Arterial Disease.

Authors:  Goren Saenz-Pipaon; Esther Martinez-Aguilar; Josune Orbe; Arantxa González Miqueo; Leopoldo Fernandez-Alonso; Jose Antonio Paramo; Carmen Roncal
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.